Fiche centre
Montpellier University Hospital
Montpellier — France
Essais liés3clinical trials
VilleMontpellierlocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05210621
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| UNZUELUZON ALS — Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients | Sclérose latérale amyotrophique | À vérifier | NCT07737977 | UNZUELUZON ALS — Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients | NOT_YET_RECRUITING |
| PREPCOV — Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection | Lupus | Non applicable | NCT04481633 | PREPCOV — Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT05210621 | CONSONANCE EX — LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB | ACTIVE_NOT_RECRUITING |